🔗 Share this article

Given that the United States proceeds with unprecedented adjustments to its immunization schedules, one figure has surfaced in a surprising turn: Høeg, a US-based physician and epidemiologist who first made her name by expressing skepticism about COVID-19 vaccinations throughout the global health crisis and has focused upon possible deaths following Covid immunization in her short tenure at the US Food and Drug Administration (FDA).

Scheduled Shifts to Childhood Immunization Schedule

Public health authorities had intended to announce sweeping changes to the pediatric immunization program in December, aligning the US with Denmark’s national calendar, sources say – a major change that would put the US out of alignment with much of the international standard with little proof for improved outcomes. The planned update has been postponed until the coming year.

Rather than the director of the vaccine center, Tracy Beth Høeg is listed to speak at the gathering. She was just designated interim head of the FDA’s drug evaluation center, the fifth individual to head the division this year.

A Shift at the Agency

Høeg's temporary position could signify a closer partnership between the pharmaceutical and biologics branches as Dr. Høeg and Prasad consolidate power at the FDA – and it signals a greater focus upon dismantling already-approved vaccines at the FDA.

Høeg has repeatedly called for discontinuing some pediatric immunization guidelines in the US so as to align more in line with the Danish model, a country with nationalized medicine and a citizenry roughly the population of Wisconsin’s.

In her initial statements, she has continued to focus on immunizations – traditionally the responsibility of Prasad, head of the FDA’s vaccine center – rather than drug regulation.

Concerns Over Expertise

Dr. Høeg has little discernible background in medication creation, regulation or administrative roles, which has been customary for former leaders of the CBER. She has worked at the FDA as a key advisor to the FDA chief and CBER since spring.

“It seems she lacks to have the necessary background” for leading the drug-regulation department, said Jonathan Howard. “She’s never run a clinical trial. She is not versed in managing a major agency. She is not an expert in pharmaceutical oversight.”

Past heads of the center would “grasp laws and regulations and the research of drug development”, said Dr. Janet Woodcock. “Clearly, she lacks the sort of resume that former directors who led CBER have had.”

The drug center has an vast portfolio at the FDA, Woodcock emphasized.

“Everybody just pays attention on the new drug program, but the generic drug division clears thousands of generic drugs. There’s a biosimilars division, OTC medication office and more, and each of these have to be looked after,” she said. “The responsibility you neglect, that’s the thing that I always told people is going to bite you.”

There is also, a significant administrative element to the job, which oversees in excess of 5,000 staff members. “It’s a massive management job, if you do it right,” she concluded.

Official Statement and Contentious Initiatives

In response to inquiries about Høeg’s fitness for the role and whether this selection indicates more teamwork among regulatory chiefs on vaccines, a representative responded that the “questions rely on inaccurate assumptions”.

“Her experience aligns with the duties of her position,” the representative said, pointing to the time Høeg spent guiding the agency head on “drug safety and oversight research, including computational safety modeling and vaccine surveillance”.

In her interim role, Høeg takes over the commissioner’s recently launched expedited review system, a disputed expedited medication authorization process that reportedly concerned her former heads. “By what process are these drugs being selected for this expedited pathway? Who makes the choices?” Dr. Howard questioned. “There’s a lot of secrecy going on at the FDA right now.”

In general, he remarked, “the Food and Drug Administration seems to be moving towards less stringent rules of most medications, aside from shots.”

Documented History on Immunizations

With vaccines, Dr. Høeg has a more documented, if troubling, past, some experts said. She published a research paper using unverified volunteer-provided data to assess the frequency of heart inflammation following Covid vaccination. She counseled the Florida top health official Dr. Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccines are more dangerous than they are.

Included in her “wish list” for the incoming federal leadership featured revising regulations for novel immunizations and discontinuing “unnecessary” immunizations, she stated after the election on a podcast. At the FDA, Dr. Høeg has reportedly proposed barring teenage boys from receiving Covid vaccinations.

“She’s an all-around dogmatist who begins with her preconceived notions and tailors the evidence to retrofit the science in a very disingenuous, fraudulent manner,” Dr. Howard stated.

Taking Control and a “Push for Payback”

Dr. Høeg joined fellow contrarians, {like|